<DOC>
	<DOCNO>NCT02585674</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority MyStar DoseCoach ( Long-acting Insulin Glargine Titration Meter ) device-supported treat-to-target regimen relative routine titration regimen percentage patient reach glycemic target , ie , mean fast self-monitored plasma glucose ( FSMPG ) value within target range 90-130 mg/dL ( 5.0-7.2 mmol/L ) without severe hypoglycemic episode 16-week on-treatment period . Secondary Objective : To assess efficacy , safety , adherence/satisfaction MyStar DoseCoach</brief_summary>
	<brief_title>Comparison MyStar DoseCoach Routine Titration Adult Patients With Type 2 Diabetes Mellitus Using Toujeo</brief_title>
	<detailed_description>The maximum study duration 21 week per patient consist 4-week screening period , 16-week treatment period , 1-week follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus diagnose least one year screen visit . Patients insulin na√Øve ( consider investigator appropriate candidate basal insulin therapy ) , treat basal insulin insulin . HbA1c 7.5 % 11 % ( inclusive ) screening . Fasting SMPG &gt; 130 mg/dL first screen FSMPG &gt; 130 mg/dL randomization . Signed informed consent . Exclusion criterion : Aged &lt; 18 year . Diabetes type 2 diabetes mellitus . MyStar DoseCoach device appropriate patient use device otherwise contraindicate ( opinion Investigator ) . Conditions/situations contraindication offlabel use accord Summary Product Characteristics ( SmPCs ) Oral AntiDiabetes Drugs ( OADs ) and/or GLP1 receptor agonist applicable ( prescribe ) , insulin glargine define national product label . Patients stable dose glucose lower therapy include OADs , GLP1 receptor agonist , basal insulin therapy , last 3 month ( stable basal insulin therapy define maximum change insulin dose +/ 20 % ) . Patients use mealtime insulin ( short act analogue , human regular insulin , premix insulin ) 10 day last 3 month screen visit . Patients hypoglycemia unawareness . Patients severe hypoglycemia past 90 day . Hospitalization past 30 day . Use systemic glucocorticoid ( exclude topical application inhale form ) one week within 90 day prior time screen . Unable meet specific protocol requirement ( eg , inability perform blood glucose measurement , manage insulin glargine administration , deem unlikely safely manage titration base guidance health care provider HCP , etc . ) , medical condition patient legal guardianship . Patients cognitive disorder , dementia , neurologic disorder would affect patient 's ability participate study , include inability understand study requirement give complete information adverse symptom . Conditions/situations : Patients conditions/concomitant disease preclude safe participation study ( eg , active malignant tumor , major systemic disease , presence clinically significant diabetic retinopathy presence macular edema likely require treatment within study period , etc . ) , Patients unable fully understand study document complete . Patients caregiver together fulfill study requirement eligible , Patient Investigator SubInvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Within last 3 month prior screen : history myocardial infarction , unstable angina , acute coronary syndrome , revascularization procedure , stroke require hospitalization . Severe uncontrolled Congestive Heart Failure ( New York Heart Association [ NYHA ] functional classification III IV ) ; inadequately control hypertension time screen rest systolic diastolic blood pressure &gt; 180 mmHg &gt; 95 mmHg , respectively . Pregnant breastfeed woman woman intend become pregnant study period glycemic control may unstable insulin dos may variable period . Women childbearing potential ( premenopausal , surgically sterile least 3 month prior time screen ) must use effective contraceptive method throughout study . Effective method contraception include barrier method ( conjunction spermicide ) , hormonal contraception , use intrauterine device ( IUD ) intrauterine hormonereleasing system ( IUS ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>